OncoMatch/Clinical Trials/NCT06232096
A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.
Is NCT06232096 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies MBS314 for relapsed or refractory multiple myeloma.
Treatment: MBS314 — This is a Phase I/Ⅱ, multicenter, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics(PD) and efficacy of a novel asymmetric trivalent tri-specific humanized antibody, MBS314, administered by intravenous (IV) infusion in participants with relapsed or refractory multiple myeloma. This entry-to-human study is divided in 2 parts: a dose escalation part (Phase Ⅰa) and an expansion part (Phase Ⅰb/Ⅱ).
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-myeloma treatment
Previously received anti-myeloma treatment within the specified time frame prior to the first administration.
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify